LFSC vs XBI
F/m Emerald Life Sciences Innovation ETF against State Street SPDR S&P Biotech ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
13%
15 shared positions
Fee gap
19 bp
XBI is cheaper
1-year return gap
4.8 pts
XBI is ahead
Larger fund
XBI
$9.9B
Side by side
| LFSC | XBI | |
|---|---|---|
| Fund | F/m Emerald Life Sciences Innovation ETF | State Street SPDR S&P Biotech ETF |
| Issuer | F/m Investments | State Street SPDR |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.54% | 0.35% |
| Assets | $118M | $9.9B |
| Average daily dollar volume | $111K | $1.4B |
| Listed | Oct 30, 2024 | Jan 31, 2006 |
| FrenzyCap score | 36 | 96 |
| 1-month return | −6.1% | −1.9% |
| 3-month return | −5.7% | −1.0% |
| Year to date | +16.4% | +26.1% |
| 1-year return | +41.1% | +45.8% |
| 30-day volatility | 23.2% | 27.0% |
| Worst drawdown, 1 year | −16.3% | −11.9% |
| Trailing 12-month yield | — | 0.35% |
| Holdings | 40 | 166 |
| Top 10 weight | 54.7% | 16.9% |
| Look-through P/E | — | — |
| Holdings vs fair value | −4.0% | +5.8% |
| Holdings above 200-day average | 55% | 62% |
| Net flow, latest 3 reported months | +$1.2M thru May 2026 | +$1.3B thru Jun 2026 |
| 30-day implied volatility | — | 31.2% |
| Holdings as of | as of May 31, 2026SEC filing | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
52% of LFSC · 15% of XBI
Sector mix of the stock holdings
| Sector | LFSC | XBI | Gap |
|---|---|---|---|
| Health Care | 88.3% | 99.2% | −10.9% |
| Technology | 2.2% | 0.0% | +2.2% |
| Financials | 0.0% | 0.7% | −0.7% |
| Industrials | 0.4% | 0.0% | +0.4% |
More: full overlap table · LFSC holdings · XBI holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.